This review summarizes current data and the results of the authors’ own investigations of the neurotropic, psychoactive, and analgesic properties of benzimidazole and its derivatives. Using a series of compounds of this class as a examples, different aspects of the actions of benzimidazoles on the nervous system of lab animals (mollusks, mice, rats, cats) are considered. The efficacy of benzimidazoles is shown to be due to actions on a number of important physiological mechanisms regulating the functional state of nerve cells and neurotransmitter systems, inflammation processes, and pain.
Similar content being viewed by others
References
S. B. Seredenin, Yu. D. Ignatov, A. I. Vislobokov, et al., “Effects of Afobasol on transmembrane ion current in mollusk neurons,” Eksperim. Klin. Farmakol., 68, No. 5, 3–6 (2005).
A. I. Vislobokov, Yu. D. Ignatov, and S. B. Seredenin, “Changes in the electrical activity of neurons in the presence of Afobasol,” Eksperim. Klin. Farmakol., 75, No. 6, 3–7 (2012).
A. I. Vislobokov, K. N. Mel’nikov, and P. D. Shabanov, “Changes in ion currents in neurons on extra- and intracellular exposure to Afobasol and bupivacaine,” Obz. Klin. Farmakol. Lekarst. Ter., 12, No. 3, 50–55 (2014).
A. P. Galenko-Yaroshevskii, L. L. Katalymov, V. V. Shurekov, and A. V. Kiselev, “Decreases in the pH of the external solution slow the rate of blockade of the conductivity of A-fibers of the sciatic nerve by the imidazobenzimidazole derivative RU-1117,” Kubansk. Nauchn. Med. Vestn., 113, No. 8, 29–33 (2009).
A. P. Galenko-Yaroshevskii, L. L. Katalymov, V. V. Shurekov, and A. V. Kiselev, “Decreases in the pH of the external solution weakens blockade of the conductivity of A-fibers of the sciatic nerve by the imidazobenzimidazole derivative RU-353,” Kubansk. Nauchn. Med. Vestn., 113, No. 8, 33–36 (2009).
T. V. Gamma, “Behavioral reactions of rats on exposure to various benzimidazole derivatives at ultra-low concentrations,” Uchen. Zap. Tavrich. Nats. Univ. im. Vernadskogo. Ser. Biol. Khim., 26, No. 1, 30–36 (2013).
T. V. Gamma, I. V. Epishkin, I. I. Korenyuk, et al., “Psychotropic effects of benzimidazole in experimental models of stress in rats,” Uchen. Zap. Tavrich. Nats. Univ. im. Vernadskogo. Ser. Biol. Khim., 22, No. 2, 16–23 (2009).
T. V. Gamma and I. I. Korenyuk, “Effects of Bemitil and benzimidazole on the behavior of rats in the open field test,” Neirofiziologiya, 38, No. 1, 71–76 (2006).
T. V. Gamma, I. I. Korenyuk, D. R. Khusainov, et al., “Analgesic properties of benzimidazole,” Uchen. Zap. Tavrich. Nats. Univ. im. Vernadskogo. Ser. Biol. Khim., 23, No. 2, 66–71 (2010).
O. Yu. Grechko, A. A. Spasov, D. M. Shtareva, and A. I. Rashchenko, “Studies of the receptor mechanism of the analgesic actions of compound RU-1205,” Vestn. Volgograd. Gos. Med. Univ., 1, No. 49, 61–63.
A. V. Kataev and T. R. Gizatullin, “Effects of a benzimidazole derivative containing a dioxothietane ring on the sequelae of psychoemotional stress induced in animals by physical loading,” Kazan. Med. Zh., 96, No. 1, 56–60 (2015).
O. I. Kolotilova and I. I. Korenyuk, “Effects of Bemitil on the electrical activity of the aminergic systems and cerebral cortex in conscious cats,” Neirofiziologiya, 41, No. 3, 218–225 (2009).
O. I. Kolotilova, V. B. Pavlenko, A. M. Kulichenko, et al., “Effects of Bemitil on the activity of the noradrenergic and serotoninergic neurons in the brainstem and the EEG in conscious cats,” Neirofiziologiya, 37, No. 3, 235–243 (2005).
I. I. Korenyuk, T. V. Gamma, D. R. Khusainov, et al., Neurotropic Effects of Chemical Compounds of Different Classes and the Possible Mechanisms of their Actions, DIAIPI, Simferopol (2012).
Yu. A. Polkovnikova, E. F. Stepanova, O. S. Gudyrev, and M. V. Pokrovskii, “A comparative study of the parameters of orientational behavior and emotionality in rats in the open field test on exposure to original medicinal formulations of Afobasol,” Vestn. Voronezh. Gos. Univ. Ser. Khim. Biol. Farm., No. 1, 192–195 (2011).
F. G. Razumnaya, F. Kh. Kamilov, O. M. Kapuler, and N. A. Mufazalova, “The pharmacology of Afobasol,” Fundam. Issled., 7, 848–855 (2014).
S. B. Seredenin and M. V. Voronin, “Neuroreceptor mechanisms of action of Afobasol (a discussion),” Zh. Psikhiatr. Psikhofarmakoter., 15, No. 1, 59–61 (2013).
S. B. Seredenin, Yu. D. Ignatov, M. A. Yarkova, et al., “Effects of Afobasol on transmembrane ion currents in neurons in a mollusk,” Eksperim. Klin. Farmakol., 68, No. 5, 3–6 (2005).
S. B. Seredenin and V. A. Kraineva, “Neuroprotective properties of Afobasol in repeated modeling of hemorrhagic stroke in elderly rats,” Eksperim. Klin. Farmakol., 72, No. 1, 24–28 (2009).
I. V. Silkina, T. S. Gan’shina, S. B. Seredenin, and R. S. Mirzoyan, “A GABAergic mechanism for the cerebrovascular and neuroprotective effects of Afobasol and Picamilon,” Eksperim. Klin. Farmakol., 68, No. 1, 20–24 (2005).
A. A. Spasov, K. Yu. Kalitin, O. Yu. Grechko, and V. A. Anisimova, “Antiepileptic activity of the new benzimidazole derivative RU-1205,” Byull. Eksperim. Biol. Med., 160, No. 9, 320–323 (2015).
A. A. Spasov, L. A. Smirnova, O. Yu. Grechko, et al., “Pharmacokinetic and analgesic effects of an injectable formulation of the new imidazobenzimidazole compound RU-1205 with κ agonist activity,” Biomed. Khim., 61, No. 5, 636–639 (2015).
A. A. Spasov, M. V. Chernikov, and S. T. Kiabiya, “Analgesic activity of 5-HT3 receptor antagonists,” Byull. Eksperim. Biol. Med., 139, No. 4, 416–419 (2005).
A. A. Spasov, M. V. Chernikov, D. S. Yakovlev, and V. A. Anisimova, “Studies of the antiserotonin activity of derivatives of tricyclic benzimidazole systems,” Khim.-Farm. Zh., 40, No. 11, 23–26 (2006).
I. A. Tregubova, V. A. Kosolapov, A. A. Spasov, and V. A. Anisimova, “Experimental study of the effects of a new antioxidant substance on learning and memory,” Byull. Eksperim. Biol. Med., 156, No. 12, 757–759 (2013).
I. V. Cheretaev, “Effects of ultra-low concentrations of 2-aminomethylbenzimidazole on behavior in rats in the Porsolt test in health and on the background of activation of the dopaminergic system with Yumex,” Molodoi Uchenyi, 19, No. 78, 100–104 (2014).
I. V. Cheretaev and I. V. Epishkin, “Comparison of the antistress and anxiolytic effects of ultra-low concentrations of 2-aminomethylbenzimidazole and Sibazon in the behavior open field test,” in: 78th Summary Sci.-Applied Conference, Krasnoyarsk (2014), pp. 706–708.
I. V. Cheretaev, I. I. Korenyuk, T. V. Gamma, and D. R. Khusainov, “Effects of ultra-low concentrations of benzimidazole on the behavior of rats in the Porsolt test in normal conditions and on the background of activation of the dopaminergic system with Yumex,” Uchen. Zap. Tavrich. Nats. Univ. im. Vernadskogo. Ser. Biol. Khim., 27, No. 4, 93–99 (2014).
K. C. Achar, K. M. Hosamani, and H. R. Seetharamareddy, “In-vivo analgesic and anti-inflammatory activities of newly synthesized benzimidazole derivatives,” Eur. J. Med. Chem., 45, No. 5, 2048–2054 (2010).
S. Dixit, P. K. Sharma, and N. Kaushik, “Synthesis of novel benzimidazole derivatives: as potent analgesic agent,” Med. Chem. Res., 22, No. 2, 900–904 (2013).
T. V. Gamma, I. I. Korenyuk, M. Y. Baevsky, et al., “Effects of Some Benzimidazole Derivatives on Electrical Activity in Molluscan Neurons,” Neurophysiology, 34, No. 2–3, 147–149 (2002).
T. V. Hamma and I. I. Koreniuk, “Effect of benzimidazole and its derivatives on electrical activity of Helix albescens Rossm. neurons and behavior of rats,” Fiziol. Zh., 53, No. 5, 53–66 (2007).
M. Hasegawa, N. Nishigaki, Y. Washio, et al., “Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors,” J. Med. Chem., 50, No. 18, 4453–4470 (2007).
R. S. Keri, A. Hiremathad, S. Budagumpi, and B. M. Nagaraja, “Comprehensive review in current developments of benzimidazole-based medicinal chemistry,” Chem. Biol. Drug Des., 86, No. 1, 19–65 (2015).
I. I. Kolotilova, I. I. Koreniuk, and Y. O. Fokina, “Modification of impulse activity of cat brainstem monoaminergic cells caused by Bemitil,” Fiziol. Zh., 54, No. 5, 71–74 (2008).
S. Kostic-Rajacic, V. Šoškic, and J. Joksimovic, “Mixed dopaminergic/ serotonergic properties of several 2-substituted 4-[2-(5-benzimidazole) ethyl]-1-arylpiperazines,” Archiv der Pharmazie, 331, No. 1, 22–26 (1998).
G. Mariappan, R. Hazarika, F. Alam, et al., “Synthesis and biological evaluation of 2-substituted benzimidazole derivatives,” Arabian. J. Chem., 8, No. 5, 715–719 (2015).
B. G. Mohamed, M. Abdel-Alim, and M. Hussein, “Synthesis of 1-acyl-2-alkylthio-1,2,4-triazolobenzimidazoles with antifungal, anti-inflammatory and analgesic effects,” Acta Pharmacol., 56, No. 1, 31–48 (2006).
A. A. Spasov, I. N. Ijozhitsa, L. I. Bugaeva, and V. A. Anisimova, “Benzimidazole derivatives: spectrum of pharmacological activity and toxicological properties (a review),” Pharmac. Chem. J., 33, No. 5, 232–243 (1999).
S. Surech, P. K. Blessi, P. Maharaj, et al., “Synthesis of benzimidazole- isatin derivatives for analgesic activity,” Asian Pharmac. Clin. Res., 6, No. 1, 65–67 (2013).
H. Zarrinmayeh, A. M. Nunes, P. L. Ornstein, et al., “Synthesis and evaluation of a series of novel 2-(4-chlorophenoxy)methyl]benzimidazoles as selective neuropeptide YY1 receptor antagonists,” J. Med. Chem., 41, 2709–2719 (1998).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Rossiiskii Fiziologicheskii Zhurnal imeni I. M. Sechenova, Vol. 103, No. 4, pp. 381–390, April, 2017.
Rights and permissions
About this article
Cite this article
Cheretaev, I.V., Korenyuk, I.I. & Nozdrachev, A.D. Neurotropic, Psychoactive, and Analgesic Properties of Benzimidazole and Its Derivatives: Physiological Mechanisms. Neurosci Behav Physi 48, 848–853 (2018). https://doi.org/10.1007/s11055-018-0639-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-018-0639-8